{
    "clinical_study": {
        "@rank": "95878", 
        "arm_group": [
            {
                "arm_group_label": "Gemfibrozil", 
                "arm_group_type": "Experimental", 
                "description": "Gemfibrozil 600 mg by mouth twice daily for 48 weeks"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo capsule by mouth twice daily for 48 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating\n      microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact\n      cognition and mild cognitive impairment"
        }, 
        "brief_title": "Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Preclinical Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "detailed_description": {
            "textblock": "Double-blind, placebo controlled, parallel-design.  48 cognitively-intact subjects, and 24\n      subjects with early cognitive decline (CDR 0.5) will be randomly assigned to treatment with\n      gemfibrozil (600 mg orally twice a day) or placebo for 52 weeks. Safety assessments will\n      include routine assessment of adverse events, safety labs, and brain magnetic resonance\n      imaging."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Participants must meet all of the following inclusion criteria in order to participate in\n        the study:\n\n          1. Men or women aged 65-90, inclusive.\n\n          2. Stable medical condition for three months prior to screening visit, with no\n             clinically significant abnormalities of hepatic, renal, and hematologic function\n             defined as follows: Platelets > 100,000, Serum creatinine \u2264 1.6 mg/dL, aspartate\n             aminotransferase (AST) or alanine aminotransferase (ALT) \u2264 1.5 upper limit of normal,\n             No clinically significant abnormalities of other laboratory studies (CBC, chemistry\n             panel)\n\n          3. Non-diabetic or well controlled diabetes confirmed by fasting serum glucose <126\n             mg/dL.\n\n          4. Stable medications for 4 weeks prior to screening visit.\n\n          5. Physically acceptable for this study as confirmed by medical history, physical exam,\n             neurological exam and clinical tests.\n\n               -  Exceptions to these criteria may be considered on a case-by-case basis, at the\n                  discretion of the Project Director.\n\n        Exclusion Criteria:\n\n          1. Female participants that are pregnant or of childbearing potential.\n\n          2. Unstable medical conditions for three months prior to screening visit such as poorly\n             controlled blood pressure, diabetes, or breathing problems\u2026etc.\n\n          3. Clinically significant abnormalities on liver, kidney or other blood tests\n\n          4. Significant neurologic disease such as Alzheimer's disease, Parkinson's disease,\n             stroke, brain tumor, multiple sclerosis or seizure disorder.\n\n          5. Major depression in past 12 months (DSM-IV criteria), major mental illness such as\n             schizophrenia, or recent (in past 12 months) alcohol or substance abuse.\n\n          6. History of invasive cancer within the past two years.\n\n          7. Contra-indications to lumbar puncture (bleeding disorder, platelet count < 100,000,\n             anticoagulant treatment, major structural abnormality or sepsis in the area of the\n             lumbosacral spine that would make a lumbar puncture technically difficult).\n\n          8. Use of any investigational agents within 30 days prior to screening.\n\n          9. Contra-indications to MRI (metallic implants, pacemaker, shrapnel, ect\u2026)\n\n         10. Sensitivity, intolerance, or allergies to gemfibrozil or any previous reaction to any\n             cholesterol lowering medicine.\n\n         11. Major surgery within eight weeks prior to the Baseline Visit.\n\n         12. Blindness, deafness, language difficulties or any other disability which may prevent\n             the potential participant from participating or cooperating in the protocol.\n\n         13. Physically unacceptable for this study as confirmed by medical history, physical\n             exam, neurological exam and clinical tests.\n\n               -  Exceptions to these criteria may be considered on a case-by-case basis, at the\n                  discretion of the examining study physician.\n\n        Excluded Medications:\n\n          1. Experimental drugs\n\n          2. Repaglinide\n\n          3. \"Statins\" including but not limited to atorvastatin (Lipitor), fluvastatin (Lescol),\n             lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin\n             (Zocor), or any combination medicines containing these drugs.\n\n          4. Coumadin, warfarin, heparin, lovenox, Xarelto, apixaban or other anticoagulants.\n             (Antiplatelet therapy is acceptable).\n\n        NOTE: If these drugs are discontinued 4 weeks or more before screening, then the\n        participant can be eligible for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "90 Years", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045056", 
            "org_study_id": "R01AG042419"
        }, 
        "intervention": [
            {
                "arm_group_label": "Gemfibrozil", 
                "intervention_name": "Gemfibrozil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Gemfibrozil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alzheimer disease", 
            "mild cognitive impairment", 
            "normal cognition"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "contact": {
                "email": "sarah.tarrant@uky.edu", 
                "last_name": "Sarah Tarrant, MSW", 
                "phone": "859-323-1331"
            }, 
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40536-0230"
                }, 
                "name": "University of Kentucky"
            }, 
            "investigator": {
                "last_name": "Gregory A Jicha, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease", 
        "overall_contact": {
            "email": "sarah.tarrant@uky.edu", 
            "last_name": "Sarah Tarrant, MSW", 
            "phone": "859-323-1331"
        }, 
        "overall_official": {
            "affiliation": "University of Kentucky", 
            "last_name": "Gregory A Jicha, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events reported during the course of the trial", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "MicroRNA-107 levels will be measured in serum and cerebrospinal fluid", 
                "measure": "microRNA-107 levels", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "Beta-amyloid 1-40 and 1-42 levels will be measured in cerebrospinal fluid at baseline and at 48 weeks", 
                "measure": "beta-amyloid levels", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The FCSRT is a sensitive measure of memory performance that will be measured at baseline and after 48 weeks of gemfibrozil treatment", 
                "measure": "Free and cued selective reminding test (FCSRT)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "The PAL is a sensitive, computerized measure of memory performance that will be measured at baseline and after 48 weeks of gemfibrozil treatment", 
                "measure": "Paired associates learning (PAL)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "University of Kentucky", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Kentucky", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}